Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Net Margin (2016 - 2025)

Historic Net Margin for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to 10.7%.

  • Arrowhead Pharmaceuticals' Net Margin rose 70194200.0% to 10.7% in Q4 2025 from the same period last year, while for Dec 2025 it was 21.41%, marking a year-over-year increase of 260028100.0%. This contributed to the annual value of 3.63% for FY2025, which is 171732400.0% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Net Margin is 10.7%, which was up 70194200.0% from 6.29% recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Net Margin registered a high of 67.77% during Q1 2025, and its lowest value of 7008.72% during Q4 2024.
  • In the last 5 years, Arrowhead Pharmaceuticals' Net Margin had a median value of 165.54% in 2021 and averaged 809.91%.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Net Margin crashed by -37454900bps in 2023, and later surged by 70194200bps in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Net Margin stood at 229.13% in 2021, then skyrocketed by 71bps to 66.85% in 2022, then crashed by -5603bps to 3812.33% in 2023, then plummeted by -84bps to 7008.72% in 2024, then surged by 100bps to 10.7% in 2025.
  • Its Net Margin stands at 10.7% for Q4 2025, versus 6.29% for Q3 2025 and 643.4% for Q2 2025.